Chronic Lymphocytic Leukemia
What's New
Last Posted: Jul 05, 2023
- Machine Learning for Diagnosis and Screening of Chronic Lymphocytic Leukemia Using Routine Complete Blood Count (CBC) Results.
Regina Padmanabhan et al. Stud Health Technol Inform 2023 305279-282 - Cytogenetic Heterogeneity in Chronic Lymphocytic Leukemia.
Pina J Trivedi et al. Journal of the Association of Genetic Technologists 2023 49(1) 4-9 - A survival prediction model and nomogram based on immune-related gene expression in chronic lymphocytic leukemia cells.
Huang Han-Ying et al. Frontiers in medicine 2023 91026812 - The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review.
Kleinstern Geffen et al. Leukemia & lymphoma 2022 1-11 - Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia.
Lampson Benjamin L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 JCO2200269 - Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features.
Robbe Pauline et al. Nature genetics 2022 11 - Molecular map of chronic lymphocytic leukemia and its impact on outcome.
Knisbacher Binyamin A et al. Nature genetics 2022 8 - Explainable machine learning for chronic lymphocytic leukemia treatment prediction using only inexpensive tests.
Meiseles Amiel et al. Computers in biology and medicine 2022 145105490 - Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia via Data Mining Mutation Databases.
Soussi Thierry et al. Frontiers in oncology 2022 12808886 - Artificial intelligence-assisted mapping of proliferation centers allows the distinction of accelerated phase from large cell transformation in chronic lymphocytic leukemia.
El Hussein Siba et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022 - Evaluation of a Prognostic Epigenetic Classification System in Chronic Lymphocytic Leukemia Patients.
Grimm Christina et al. Biomarker insights 2022 1711772719211067972 - Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
Burger Jan A et al. Leukemia & lymphoma 2022 1-12 - Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia.
Kanagal-Shamanna Rashmi et al. Leukemia & lymphoma 2021 1-11 - Cellular and humoral Immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia
ZL Lyski et al, MEDRXIV, November 5, 2021 - Altered DNA Methylation Profiles in SF3B1 Mutated CLL Patients.
Pacholewska Alicja et al. International journal of molecular sciences 2021 22(17) - An overview of genetic predisposition to familial hematological malignancies.
Hamadou Walid Sabri et al. Bulletin du cancer 2021 - Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Molica Stefano et al. Clinical lymphoma, myeloma & leukemia 2020 Oct - [Fluorescence in Situ Hybridization for Detecting Molecular Cytogenetic Abnormalities of Chronic Lymphocytic Leukemia].
Zhang Hai-Ying et al. Zhongguo shi yan xue ye xue za zhi 2020 Oct 28(5) 1474-1479 - Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Kater Arnon P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Sep JCO2000948 - Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia.
Lee Jimmy et al. The Journal of molecular diagnostics : JMD 2020 Jun
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:May 14, 2024
- Content source: